| Literature DB >> 27420916 |
Erin Munkácsy1,2, Maruf H Khan1,3,4, Rebecca K Lane1, Megan B Borror1, Jae H Park1, Alex F Bokov5, Alfred L Fisher4,6,7, Christopher D Link8, Shane L Rea1,3.
Abstract
Mitochondrial dysfunction underlies numerous age-related pathologies. In an effort to uncover how the detrimental effects of mitochondrial dysfunction might be alleviated, we examined how the nematode C. elegans not only adapts to disruption of the mitochondrial electron transport chain, but in many instances responds with extended lifespan. Studies have shown various retrograde responses are activated in these animals, including the well-studied ATFS-1-dependent mitochondrial unfolded protein response (UPRmt). Such processes fall under the greater rubric of cellular surveillance mechanisms. Here we identify a novel p38 signaling cascade that is required to extend life when the mitochondrial electron transport chain is disrupted in worms, and which is blocked by disruption of the Mitochondrial-associated Degradation (MAD) pathway. This novel cascade is defined by DLK-1 (MAP3K), SEK-3 (MAP2K), PMK-3 (MAPK) and the reporter gene Ptbb-6::GFP. Inhibition of known mitochondrial retrograde responses does not alter induction of Ptbb-6::GFP, instead induction of this reporter often occurs in counterpoint to activation of SKN-1, which we show is under the control of ATFS-1. In those mitochondrial bioenergetic mutants which activate Ptbb-6::GFP, we find that dlk-1, sek-3 and pmk-3 are all required for their life extension.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27420916 PMCID: PMC4946786 DOI: 10.1371/journal.pgen.1006133
Source DB: PubMed Journal: PLoS Genet ISSN: 1553-7390 Impact factor: 5.917
Fig 1Evidence for a novel signaling pathway activated subsequent to mitochondrial disruption.
(A) Among the ten most highly upregulated genes activated following mitochondrial disruption by spg-7 RNAi, tbb-6 alone does not require atfs-1 for its induction (microarray data from GEO dataset GSE38196). See also S1 Table. (B) 40 of the 148 atfs-1 independent genes activated following spg-7 disruption contain a predicted EOR-1 binding motif (shown in LOGO form aligned against the consensus EOR-1 site which was identified through the C. elegans ModENCODE project (top panel)). (C) 42 of the 148 atfs-1 independent genes activated following spg-7 disruption contain a C/EBP-like promoter motif (shown in LOGO form aligned against the promoter motif bound by human C/EBPβ (top panel)). (D) Venn diagram illustrating the degree of overlap between groups of atfs-1 independent genes that contain C/EBPβ -like, EOR-1 or DAF-16 promoter elements. (E) Promoter region of tbb-6: Sites A and B match the human C/EBPβ consensus motif shown in panel (C). ChiP-Seq data from the C. elegans ModENCODE project [52], reveals a functional DAF-16 binding site, as well as a functional PHA-4 binding site [Stv. L1(rep 2)–starved L1 larvae, 2nd replicate sample set, L4/YA—larval stage 4/young adult].
Fig 2Ptbb-6::GFP reporter activation following mitochondrial ETC disruption.
(A) RNAi-mediated knockdown of mitochondrial respiratory chain subunits differentially induces Ptbb-6::GFP reporter expression relative to Pgst-4::GFP and Phsp-6::GFP. Shown are representative fluorescence images from a selection of subunits targeted in each complex. Quantified data of multiple replicates for all tested subunits is provided in S1–S3 Figs. (B) Mean change in GFP reporter fluorescence (+/-SD) when the effect of RNAi treatments targeting subunits from each ETC complex are averaged. Two statistical comparisons are shown (Student’s t-test with Bonferroni correction applied for multiple comparisons): Asterisks indicate ETC complex disruptions which, on average, differ significantly in GFP fluorescence relative to knockdown of complex V subunits. Double daggers indicate ETC complex disruptions which, on average, differ significantly in GFP fluorescence relative to knockdown of complex I subunits. (*/†, p<0.01; **/††, p<0.001; ***/ǂǂǂ, p<0.00001) For complex III subunits cyc-1 and isp-1, 4d and 7d refer to 4 day—and 7-day old worms. For comparisons relative to empty vector see S4 Fig.
Fig 3Ptbb-6::GFP reporter expression defines a UPRmt independent pathway.
(A) Ptbb-6::GFP is less strongly induced by mutation of ETC subunits than by RNAi knockdown, whereas Pgst-4::GFP expression displays an opposite pattern. (B) Treatment of ctb-1(qm189) mutants with RNAi targeting complexes I, III, IV or V [nuo-2, isp-1, cco-1 and one-tenth strength atp-3, respectively], underscores the reciprocal relationship between Ptbb-6::GFP and Pgst-4::GFP reporter expression. Quantification data for both (A) and (B) is provided in S6 Fig.
Targeted screen for factors regulating Ptbb-6::GFP expression and larval development in isp-1(qm150) worms (quantified relative to vector-treated animals).
| RNAi | Gene Name | Gene Function | Development | Reference | |
|---|---|---|---|---|---|
| B0478.1 | Jun-N-terminal MAPK (stress response) | no effect | |||
| T07A9.3 | Jun-N-terminal MAPK (stress response) | no effect | no effect | ||
| ZC416.4 | Jun-N-terminal MAPK (stress response) | no effect | no effect | ||
| C49C3.10 | Jun-N-terminal MAPK (stress response) | no effect | no effect | ||
| Y51B9A.9 | Jun-N-terminal MAPK (stress response) | no effect | no effect | ||
| B0218.3 | p38 MAPK (stress response) | no effect | no effect | ||
| F42G8.3 | p38 MAPK (stress response) | no effect | no effect | ||
| F42G8.4 | p38 MAPK (stress response) | no effect | |||
| F43C1.2 | ERK MAPK (growth response factor) | no effect | no effect | ||
| W06B3.2 | ERK MAPK (development) | ||||
| W06F12.1 | nmo MAPK (development and inflammation) | no effect | no effect | ||
| C04G6.1 | MAPK | no effect | no effect | ||
| C05D10.2 | MAPK | no effect | |||
| F09C12.2 | related to MAPK | no effect | |||
| F35C8.3 | MAPKK | no effect | |||
| K08A8.1 | MAPKK | no effect | no effect | ||
| Y54E10BL.6 | MAPKK | variable | no effect | ||
| F42G10.2 | MAPKK | no effect | |||
| R03G5.2 | MAPKK | no effect | |||
| ZC449.3 | MAPKK | no effect | |||
| F35C8.2 | MAPKK | no effect | no effect | ||
| F35C8.1 | MAPKK | no effect | no effect | ||
| VZC374L.1 | MAPKK | no effect | no effect | ||
| E02D9.1 | MAPKK | no effect | no effect | ||
| F29C4.1 | MAPKKK | no effect | no effect | ||
| C05D2.1 | MAPKKK | no effect | no effect | ||
| F33E2.2 | MAPKKK | no effect | |||
| F13B9.5 | MAPKKK | no effect | no effect | ||
| F58D5.4 | MAPKKK | no effect | no effect | ||
| K11D12.10 | MAPKKK | no effect | no effect | ||
| F52F12.3 | MAPKKK | no effect | no effect | ||
| B0414.7 | MAPKKK | no effect | no effect | ||
| F59A6.1 | MAPKKK | no effect | no effect | ||
| K09B11.1 | MAPKKK | no effect | no effect | ||
| C24A1.3 | MAPKKK | no effect | no effect | ||
| Y105C5A.x | MAPKKK | no effect | no effect | ||
| F08B1.1 | dual-specificity MAPK phosphatase | [ | |||
| C04F12.8 | potential dual-specificity MAPK phosphatase | no effect | no effect | ||
| C24F3.2 | potential dual-specificity MAPK phosphatase | no effect | no effect | ||
| F13D11.3 | potential dual-specificity MAPK phosphatase | no effect | no effect | ||
| F28C6.8 | potential dual-specificity MAPK phosphatase | no effect | no effect | ||
| Y54F10BM.13 | potential dual-specificity MAPK phosphatase | ||||
| ZK757.2 | potential dual-specificity MAPK phosphatase | no effect | no effect | ||
| D1005.3 | bZIP TF; CCAAT-enhancer binding protein | no effect | no effect | [ | |
| C44C8.6 | MAP kinase activated protein kinase | [ | |||
| F26H9.6 | RAB5 GTPase ortholog | [ | |||
| C01B7.6 | E3 ubiquitin ligase | no effect | [ | ||
| F26H9.7 | ubiquitin-conjugating enzyme (E2) variant | no effect | [ | ||
| C25A1.11 | AHA-1 interacts with AHR-1 and HIF-1 | no effect | [ | ||
| ZC64.3 | POU-class homeodomain transcription factor | [ | |||
| ZK652.5 | homeodomain transcription factor | no effect | no effect | [ | |
| F52B5.5 | ortholog of human tumor suppressor p53 | no effect | no effect | [ | |
| F38A6.3 | hypoxia-induced transcription factor | no effect | no effect | [ | |
| W02C12.3 | bHLH TF; lipid metabolism | no effect | [ | ||
| T24H10.7 | bZIP TF; development | no effect | [ | ||
| F16H9.2 | nuclear hormone receptor transcription factor | no effect | no effect | [ | |
| K10C3.6 | NHR transcription factor; lipid metabolism | no effect | [ | ||
| R119.6 | TFIID transcription factor | [ | |||
| C33D3.1 | GATA-type TF; intestinal immunity | no effect | [ | ||
| C50H2.1 | neuropeptide receptor | no effect | no effect | [ | |
| Y53C10A.12 | heat-shock TF; stress and immune response | [ | |||
| K02F3.4 | immune response | no effect | no effect | [ | |
| F45E4.1 | ADP-ribosylation factor | no effect | no effect | [ | |
| ZC376.7 | mitochondrial unfolded protein | [ | |||
| K01D12.11 | cadmium responsive | no effect | [ | ||
| F52E1.13 | oxidative resistance | no effect | [ | ||
| F40F8.7 | paraquat responsive | no effect | [ | ||
| T19E7.2 | development; oxidative stress response | no effect | [ | ||
| F47H4.10 | homolog of Skp1 in | no effect | no effect | [ | |
| T16G1.4 | uncharacterized | no effect | [ | ||
| F57H12.1 | ADP-ribosylation factor | no effect | [ | ||
| F56A8.6 | mRNA cleavage | [ | |||
| F09G2.4 | cleavage and polyadenylation specificity factor | [ | |||
| D2045.6 | cullin; development | [ | |||
| R13H8.1 | forkhead box O (FOXO) transcription factor | no effect | no effect | [ | |
| C26C6.5 | ortholog of NuRD component p66 | no effect | no effect | [ | |
| F47A4.2 | mediator protein subunit | no effect | [ | ||
| C33D3.1 | GATA-type TF; intestinal immunity | no effect | [ | ||
| H13N06.3 | trehalose-6-phosphatase | variable | [ | ||
| C53A5.3 | histone deacetylase | no effect | [ | ||
| F25B4.6 | HMG-CoA synthase | [ | |||
| F32E10.4 | importin alpha nuclear transport factor | [ | |||
| C41C4.4 | ER unfolded protein response (UPR) | [ | |||
| M7.1 | E2 ubiquitin conjugating enzyme | [ | |||
| F38H4.9 | catalytic subunit of protein phosphatase 2A | [ | |||
| T27C4.4 | component of NuRD complex | [ | |||
| C25H3.6 | mediator; development | no effect | [ | ||
| ZC581.1 | serine threonine protein kinase | [ | |||
| T23H2.5 | RAB-like GTPase | no effect | [ | ||
| C35C5.1 | regulates X transcription | no effect | [ | ||
| F46A9.5 | ubiquitin ligase complex component | no effect | no effect | [ | |
| C06A8.2 | small nuclear RNA activating complex | [ | |||
| C23H3.4 | serine palmitoyltransferase; development | [ | |||
| F19B6.2 | ubiquitin selection chaperone | [ | |||
| C46C2.1 | WNK-type protein kinase homolog | no effect | no effect | [ | |
| F53F4.11 | an ortholog of human RSL1D1 | no effect | [ | ||
| F40F12.7 | CREB binding protein | [ | |||
| F31E3.1 | homeodomain transcription factor | no effect | [ | ||
| Y47G6A.23 | lipid metabolism | variable | no effect | [ | |
| R05D11.3 | nuclear transport factor; development | variable | [ | ||
| Y54E10BR.5 | signal peptidase complex subunit | no effect | no effect | [ | |
| C06A1.1 | AAA-ATPase | ||||
| C41C4.8 | AAA-ATPase | ||||
| F59E12.5 | ubiquitin selection chaperone | ||||
| F19B6.2 | ubiquitin selection chaperone | [ | |||
| K06H7.3 | VCP/Cdc48-associated (controversial role) | no effect | no effect | [ | |
| Y116A8C.12 | ADP-ribosylation factor | no effect | |||
| C06A1.1 | ubiquitin selection chaperone; ERAD | ||||
| C41C4.8 | ubiquitin selection chaperone; ERAD | ||||
| C35D10.9 | programmed cell death | no effect | no effect | [ | |
| F56D2.7 | cell-corpse engulfment during apoptosis | no effect | no effect | ||
| R13H8.1 | forkhead box O (FOXO) transcription factor | no effect | no effect | ||
| C26D10.5 | involved in cell fusions | no effect | no effect | ||
| F52E1.7 | heat-shock protein chaperone | no effect | no effect | ||
| C09H6.2 | required for polarized protein localization | no effect | |||
| F59E12.5 | ER-associated protein degradation (ERAD) | ||||
| F55B12.5 | lipid-binding transportation protein | no effect | no effect | ||
| F29B9.4 | apoptotic pathway | no effect | no effect | ||
| C03C10.4 | RAB-11 GEF activity | no effect | [ | ||
| F10D11.1 | mitochondrial superoxide dismutase | no effect | [ | ||
| C44H4.5 | TGF-beta activated kinase | no effect | no effect | ||
| F42D1.2 | tyrosine amino transferase | no effect | no effect | ||
| T04H1.9 | beta-tubulin | no effect | no effect | [ | |
| R13F6.4 | teneurin | no effect | |||
| ZK524.2 | regulator of neurotransmitter release | no effect | [ | ||
| K06H7.3 | VCP/Cdc48-associated mito stress responsive | no effect | no effect | [ | |
| D2030.9 | negative regulator of SKN-1 | [ | |||
| T20F10.1 | integrity of apical intestinal membrane | no effect | no effect | ||
| C03C10.4 | mitochondrial ribosome interacting protein | no effect |
* RNAi clone was sequence not verified
Fig 4Ptbb-6::GFP reporter expression defines a UPRmt independent pathway.
(A) RNAi knockdown of atfs-1 blocks Phsp-6::GFP expression, as reported [43], but dramatically further upregulates Ptbb-6::GFP in both isp-1(qm150) and nuo-6(qm200) worms. Surprisingly, atfs-1 RNAi also turned off Pgst-4::GFP. RNAi knockdown of skn-1 in both isp-1(qm150) and nuo-6(qm200) worms (data for latter worms is also provided in S7 Fig), turns off Pgst-4::GFP, as reported [59], but has no effect on Ptbb-6::GFP (and Phsp-6::GFP) expression. (B) Upregulation of Ptbb-6::GFP following atfs-1 removal is only observed in the context of ETC dysfunction. (C) Quantitative of atfs-1 mRNA in worms of panel (B). Bars represent mean (+/- SD); n = 3 biological replicates/condition. Asterisks indicate significant knockdown of atfs-1 mRNA on atfs-1 RNAi relative to vector (Student’s t-test, *p<0.001, **p<0.0001).
Fig 5Ptbb-6::GFP marks a new cell surveillance pathway.
(A, B) Among genes known to function epistatically to atfs-1 in its role in activating the UPRmt [26, 60], only F40F12.7/ cbp-3 is also required for Ptbb-6::GFP expression (A). The role of cbp-3 in the Ptbb-6::GFP pathway is distinct from its role in the UPRmt, since ceramide addition only replaces the requirement for cbp-3 in UPRmt activation (B). (C, D) Monoamine neurotransmission and neuromodulation are dispensable for Ptbb-6::GFP activation. Neither dietary supplementation of L-tyramine, octopamine or dopamine (C), nor genetic inactivation of catecholamine synthesis (D), alters Ptbb-6::GFP activation following mitochondrial ETC disruption. (E, F) RNAi-mediated inhibition of core MAD pathway genes strongly inhibit Ptbb-6::GFP induction by isp-1(qm150) worms. Quantitative fluorescence imaging data is provided in panel F. (n = 4–7 worms per condition; asterisks indicate significantly (p<0.025) different relative to vector-treated animals).
Fig 6Ptbb-6::GFP expression requires a MAPK signal cascade.
(A) RNAi-mediated disruption of the MAP3K/MAP2K/MAPK pathway defined by DLK-1 → SEK-3 → PMK-3 blocks induction of Ptbb-6::GFP in isp-1(qm150) worms but not Pgst-4::GFP nor Phsp-6::GFP reporter expression. Graph provides quantification of reporter expression level, normalized to vector-control RNAi (Mean+/-SD, n = 12–18 worms/ RNAi treatment). Asterisks indicate significant difference relative to vector (one-way ANOVA and ad hoc using Dunnett’s Multiple Comparisons Test, *p<0.05, **p<0.01, ***p<0.001). See also S9 Fig and S3 Table. (B) pmk-3(ok169) null mutants show the expected reduction in size upon RNAi knockdown of mitochondrial respiratory subunits, but are incapable of inducing Ptbb-6::GFP. (C) MKK-4 is not required for Ptbb-6::GFP induction following mitochondrial ETC disruption by isp-1 RNAi, unlike SEK-3. (D) Neuron-specific expression of a constitutively active form of DLK-1 acts cell autonomously to activate Ptbb-6::GFP expression. There is no induction of Ptbb-6::GFP in intestinal or other cells. (Arrows mark ventral nerve cord).
Fig 7A single MAPK is required for the induction of Ptbb-6::GFP following mitochondrial bioenergetic disruption.
(A) RNAi knockdown of the dual-specificity phosphatase vhp-1 in isp-1(qm150) worms leads to hyperactivation of Ptbb-6::GFP and L3 larval arrest. (B-D) Inhibition of pmk-3 uniquely rescues both larval arrest and blocks reporter expression among all fourteen JNK (B), p38 (C) and ERK-type (D) MAPKs.
Fig 8Role of pmk-3 in Mit mutant life extension.
(A-D) pmk-3(ok169) worms showed significantly attenuated life extension upon RNAi knockdown of specific mitochondrial ETC subunits. (E-H) isp-1(qm150) and tpk-1(qm162), but not nuo-6(qm200) or clk-1(qm30) mitochondrial ETC mutants display significantly attenuated life extension following RNAi-mediated removal of pmk-3. For these four panels, lifespan curves represent averages of two or more independent experiments. Significance values, N, and lifespan statistics are provided in S4 Table. Raw lifespan data is provided in S5 Table.
Fig 9dlk-1, sek-3 and pmk-3 are required for life extension following RNAi-mediated disruption of isp-1.
Mutations in dlk-1(ju476), sek-3(ok1276) and pmk-3(ok169) attenuate the life extending effects of isp-1 RNAi relative to wild type (N2) worms (N = 60 worms/condition). Full lifespan statistics in S4 Table.
Fig 10RNAi-mediated inhibition of tbb-6 mildly inhibits the life extension of isp-1(qm150) Mit mutants—potentially by mediating voltage-dependent anion channel (VDAC) activity.
(A) Survival analysis of isp-1(qm150) and wild type (N2) worms cultured on RNAi to tbb-6 or vector control (pL4440). The lifespan of isp-1(qm150) mutants is reduced by ~7% following knockdown of tbb-6. (Combined data from replicate experiments, Log rank test p < 0.003, N = 126–206 worms/condition). Full lifespan statistics in S4 Table. (B) C-termini of β-tubulins from various species. Non-C. elegans data derived from Fig 6A of Rostovtseva and colleagues [101]). (C) Removal of either of the two C/EBP-like motifs in the tbb-6 promoter of Ptbb-6::GFP abrogates GFP reporter expression. Transgenic lines contain mCherry under the control of the wild-type tbb-6 promoter as an internal control.